Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1984 Apr;44(1):168–174. doi: 10.1128/iai.44.1.168-174.1984

Stimulation of cell-mediated immunity by bestatin correlates with reduction of bacterial persistence in experimental chronic Salmonella typhimurium infection.

G Dickneite, F Kaspereit, H H Sedlacek
PMCID: PMC263488  PMID: 6368392

Abstract

The effect of bestatin, a low-molecular-weight immunomodulating drug isolated from Streptomyces olivoreticuli, on Salmonella typhimurium infection was elaborated. Bestatin enhanced the delayed-type hypersensitivity reaction against S. typhimurium in a dose- and time-dependent manner. Parallel to the activation of delayed-type hypersensitivity reaction, bestatin reduced the amount of persistent bacteria in livers and spleens as well as the amount of necrotic foci found in these organs. This was shown when bestatin was given either prophylactically or therapeutically. The therapeutic effect of bestatin was even seen when the drug was given in the chronic phase of the infection, i.e., 6 days after inoculation of the animals with the infectious agent. No influence of bestatin, however, could be observed on the initial multiplication rate of S. typhimurium and concomitantly on the initial mortality rate of the infected mice. As bestatin has no direct antibiotic effect on S. typhimurium, it must be concluded that the therapeutic effects of the drug on chronic infection must be solely contributed to elevation of the host's own defense mechanisms.

Full text

PDF
168

Images in this article

169Image
on p.169

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoyagi T., Suda H., Nagai M., Ogawa K., Suzuki J. Aminopeptidase activities on the surface of mammalian cells. Biochim Biophys Acta. 1976 Nov 8;452(1):131–143. doi: 10.1016/0005-2744(76)90064-4. [DOI] [PubMed] [Google Scholar]
  2. Beaman L., Benjamini E., Pappagianis D. Activation of macrophages by lymphokines: enhancement of phagosome-lysosome fusion and killing of Coccidioides immitis. Infect Immun. 1983 Mar;39(3):1201–1207. doi: 10.1128/iai.39.3.1201-1207.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bruley-Rosset M., Florentin I., Kiger N., Schulz J., Mathé G. Restoration of impaired immune functions of aged animals by chronic bestatin treatment. Immunology. 1979 Sep;38(1):75–83. [PMC free article] [PubMed] [Google Scholar]
  4. Collins F. M., Mackaness G. B., Blanden R. V. Infection-immunity in experimental salmonellosis. J Exp Med. 1966 Oct 1;124(4):601–619. doi: 10.1084/jem.124.4.601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Collins F. M., Mackaness G. B. Delayed hypersensitivity and arthus reactivity in relation to host resistance in salmonella-infected mice. J Immunol. 1968 Nov;101(5):830–845. [PubMed] [Google Scholar]
  6. Drews J. A role for immune stimulation in the treatment of microbial infections? Infection. 1980;8(1):2–4. doi: 10.1007/BF01677390. [DOI] [PubMed] [Google Scholar]
  7. Hahn H., Kaufmann S. H. The role of cell-mediated immunity in bacterial infections. Rev Infect Dis. 1981 Nov-Dec;3(6):1221–1250. doi: 10.1093/clinids/3.6.1221. [DOI] [PubMed] [Google Scholar]
  8. Hochadel J. F., Keller K. F. Protective effects of passively transferred immune T- or B-lymphocytes in mice infected with Salmonella typhimurium. J Infect Dis. 1977 May;135(5):813–823. doi: 10.1093/infdis/135.5.813. [DOI] [PubMed] [Google Scholar]
  9. Hormaeche C. E. Genetics of natural resistance to salmonellae in mice. Immunology. 1979 Jun;37(2):319–327. [PMC free article] [PubMed] [Google Scholar]
  10. Jarstrand C., Blomgren H. Increased granulocyte phagocytosis after oral administration of bestatin, a new immunomodulator. J Clin Lab Immunol. 1982 Feb;7(2):115–118. [PubMed] [Google Scholar]
  11. Kotani S., Watanabe Y., Shimono T., Harada K., Shiba T. Correlation between the immunoadjuvant activities and pyrogenicities of synthetic N-acetylmuramyl-peptides or -amino acids. Biken J. 1976 Mar;19(1):9–13. [PubMed] [Google Scholar]
  12. Levy S. B. Microbial resistance to antibiotics. An evolving and persistent problem. Lancet. 1982 Jul 10;2(8289):83–88. doi: 10.1016/s0140-6736(82)91701-9. [DOI] [PubMed] [Google Scholar]
  13. Mackaness G. B., Blanden R. V., Collins F. M. Host-parasite relations in mouse typhoid. J Exp Med. 1966 Oct 1;124(4):573–583. doi: 10.1084/jem.124.4.573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Müller W. E., Schuster D. K., Zahn R. K., Maidhof A., Leyhausen G., Falke D., Koren R., Umezawa H. Properties and specificity of binding sites for the immunomodulator bestatin on the surface of mammalian cells. Int J Immunopharmacol. 1982;4(5):393–400. doi: 10.1016/0192-0561(82)90012-1. [DOI] [PubMed] [Google Scholar]
  15. Müller W. E., Zahn R. K., Arendes J., Munsch N., Umezawa H. Activation of DNA metabolism in T-cells by bestatin. Biochem Pharmacol. 1979 Oct 15;28(20):3131–3137. doi: 10.1016/0006-2952(79)90623-3. [DOI] [PubMed] [Google Scholar]
  16. Nickol A. D., Bonventre P. F. Acquired immunity against mouse typhoid: genetic restriction and comparative efficacy of ribosomal and conventional vaccines. J Med Microbiol. 1981 Nov;14(4):419–433. doi: 10.1099/00222615-14-4-419. [DOI] [PubMed] [Google Scholar]
  17. O'Brien A. D., Metcalf E. S. Control of early Salmonella typhimurium growth in innately Salmonella-resistant mice does not require functional T lymphocytes. J Immunol. 1982 Oct;129(4):1349–1351. [PubMed] [Google Scholar]
  18. O'Brien A. D., Rosenstreich D. L., Scher I., Campbell G. H., MacDermott R. P., Formal S. B. Genetic control of susceptibility to Salmonella typhimurium in mice: role of the LPS gene. J Immunol. 1980 Jan;124(1):20–24. [PubMed] [Google Scholar]
  19. O'Brien A. D., Scher I., Campbell G. H., MacDermott R. P., Formal S. B. Susceptibility of CBA/N mice to infection with Salmonella typhimurium: influence of the X-linked gene controlling B lymphocyte function. J Immunol. 1979 Aug;123(2):720–724. [PubMed] [Google Scholar]
  20. Oka S. A review of clinical studies on bestatin, 1976--1978. Recent Results Cancer Res. 1981;76:222–231. [PubMed] [Google Scholar]
  21. Plant J., Glynn A. A. Genetics of resistance to infection with Salmonella typhimurium in mice. J Infect Dis. 1976 Jan;133(1):72–78. doi: 10.1093/infdis/133.1.72. [DOI] [PubMed] [Google Scholar]
  22. Saito M., Aoyagi T., Umezawa H., Nagai Y. Bestatin, a new specific inhibitor of aminopeptidases, enhances activation of small lymphocytes by concanavalin A. Biochem Biophys Res Commun. 1976 May 23;76(2):526–533. doi: 10.1016/0006-291x(77)90756-2. [DOI] [PubMed] [Google Scholar]
  23. Saito M., Takegoshi K., Aoyagi T., Umezawa H., Nagai Y. Stimulatory effect of bestatin, a new specific inhibitor of aminopeptidases, on the blastogenesis of guinea pig lymphocytes. Cell Immunol. 1978 Oct;40(2):247–262. doi: 10.1016/0008-8749(78)90333-7. [DOI] [PubMed] [Google Scholar]
  24. Schorlemmer H. U., Bosslet K., Sedlacek H. H. Ability of the immunomodulating dipeptide bestatin to activate cytotoxic mononuclear phagocytes. Cancer Res. 1983 Sep;43(9):4148–4153. [PubMed] [Google Scholar]
  25. Umezawa H., Ishizuka M., Aoyagi T., Takeuchi T. Enhancement of delayed-type hypersensitivity by bestatin, an inhibitor of aminopeptidase B and leucine aminopeptidase. J Antibiot (Tokyo) 1976 Aug;29(8):857–859. doi: 10.7164/antibiotics.29.857. [DOI] [PubMed] [Google Scholar]
  26. Umezawa H. New microbial secondary metabolites under preclinical development for cancer treatment. Recent Results Cancer Res. 1978;63:120–134. doi: 10.1007/978-3-642-81219-4_12. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES